Alzheimer's Association Develops First Practice Guidelines for Clinical Evaluation of Alzheimer Disease, Other Dementias
The recommendations will provide an important tool to help improve the quality of the diagnostic process, so patients receive an early and accurate diagnosis.
Andrew Satlin, MD: Lumateperone for Agitation in Patients with Dementia, Alzheimer Disease
Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.
James Hendrix, PhD: First Practice Guidelines for Clinical Evaluation of Alzheimer Disease Released
These guidelines will provide primary clinicians and the specialist community an important new tool to more accurately diagnose patients.
FDA Grants Alzheimer Biomarker Test Breakthrough Status
The FDA has granted a Breakthrough Device Designation to the Elecsys beta-Amyloid (1-42) and Elecsys Phospho-Tau (181P) cerebrospinal fluid assays, which can be used in the diagnosis of Alzheimer disease.
Neural Insights on Social Exclusion
Neurological findings tell us why decision-making functions of the brain can be altered based on certain life experiences.
Investigational Therapy TNX-102 SL Receives FDA Fast Track for Agitation in Alzheimer Disease
TNX-102 SL’s impact on sleep disturbance highlights a mechanism of action that could result in positive effects on agitation in AD.
ZX008 Significantly Reduces Seizures in Dravet Syndrome
The addition of ZX008 to background stiripentol significantly reduced the number of convulsive seizures experienced by children and young adults with Dravet syndrome.
CGRP Infusion Shows Efficacy in Cluster Headache Management
After success in migraine treatment, CGRP has now shown a positive effect on acute cluster headache in a randomized clinical trial.
FDA Accepts Sodium Oxybate Application for Children With Narcolepsy
The FDA has accepted a supplemental new drug application for sodium oxybate as a treatment for cataplexy and excessive daytime sleepiness in children with narcolepsy.
Can Neurologists Identify Patient Suicide Warnings?
Given that suicide is increasing as a public health concern, better identification of warning signs could assist in directing preventative strategies to the right people.
Positive Topline Results Announced for BAN2401 in Phase II Alzheimer Trial
The anti-amyloid protofibril antibody achieved statistical significance in its key efficacy endpoints after 18 months.
Sports and Headaches: A Risky Business Quiz
Which sports-related migraine is associated with longer recovery time, as well as cognitive, neurobehavioral, and somatic symptoms? Test your skills in this quiz.
Promising Cell Therapy Unavailable for ALS Under Right-to-Try
The autologous stem cell therapy is currently in a phase III trial.
Galcanezumab Shows Efficacy in Cluster Headache, Migraine
Phase III results have shown galcanezumab is efficacious for multiple headache conditions.
Eptinezumab Reduces Monthly Migraine Days Post-Third, Fourth Infusions
The anti-CGRP treatment continues reducing migraine days a year after patients received infusions.
Rimegepant Eases Pain, Resolves Symptoms for Acute Migraine
Rimegepant significantly reduced pain and the most bothersome symptom while showing an "excellent" safety profile for patients with acute migraine attacks.
Quarterly Infusions of Eptinezumab Highly Effective for Migraine Prevention in PROMISE 2
The intravenous quarterly CGRP inhibitor eptinezumab significantly reduced monthly migraine days compared with placebo for patients with chronic migraine.
Neurology Comic: Stress Test
We're trying to make our stress tests more realistic.
Riluzole Prolongs Late-Stage Survival in ALS
A retrospective analysis of a dose-ranging trial found that those who were administered 100-mg daily riluzole, in comparison with placebo, spend a longer period of time in stage 4 of ALS.
FDA Accepts APL-130277 Application for OFF Episodes in PD
The FDA had accepted a new drug application for APL-130277, a sublingual film version of apomorphine, as a treatment for OFF episodes in patients with Parkinson disease.
FDA Approves Cannabidiol for Lennox-Gastaut, Dravet Syndromes
The FDA has approved cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome for patients 2 years of age and older.
Gene Therapy Shows Robust Activity for Duchenne Muscular Dystrophy
A novel gene therapy has demonstrated impressive early results in a small sample of 3 children with Duchenne muscular dystrophy.
VY-AADC Gene Therapy Receives FDA RMAT Designation for Parkinson
Across 3 cohorts, the therapy showed improvements in on-time without troublesome dyskinesia, ranging from 2.1 hours to 3.5 hours.
Updated Clinical Guidelines on the Ketogenic Diet in Children with Epilepsy
Nearly a decade in the making, revised guidelines provide 8 key points for effective nonpharmacologic treatment of epilepsy in childhood.
California Startup Exploring Novel ALS Discovery Platform
A grant from the National Institute of Neurological Disorders and Stroke, which allows for concurrent phase I and II trial design review, will speed up the development of novel treatments for patients with ALS and FTD.
Ocrelizumab Delays Disability Progression in Primary Progressive Multiple Sclerosis
Those treated with ocrelizumab observed a 46% reduction in their risk of progressing to a wheelchair compared to those administered placebo treatments.
Lemborexant Shows Positive Results in Pair of Phase I Studies
The results of a pair of trials of lemborexant support phase III findings of the investigational sleep-wake regulator.
FDA Grants Priority Review to Perampanel for Pediatric Seizures
The FDA has granted a priority review designation to perampanel for 2 potential new indications for pediatric patients with seizures.
Mini Quiz: Treatment-Induced Neuropathy of Diabetes
What are the key symptoms of TIND, a rare condition that can occur after rapid normalization of blood glucose levels following prolonged periods of hyperglycemia?
Neurological Consult Using Audiovisual Tools
How effective is the telemedicine versus telephonic approach in acute care?
